Search results for "MTO"
showing 10 items of 538 documents
Kaon femtoscopy in Pb-Pb collisions at √sNN=2.76 TeV
2017
We present the results of three-dimensional femtoscopic analyses for charged and neutral kaons recorded by ALICE in Pb-Pb collisions at √ s NN = 2.76 TeV. Femtoscopy is used to measure the space-time characteristics of particle production from the effects of quantum statistics and final-state interactions in two-particle correlations. Kaon femtoscopy is an important supplement to that of pions because it allows one to distinguish between different model scenarios working equally well for pions. In particular, we compare the measured three-dimensional kaon radii with a purely hydrodynamical calculation and a model where the hydrodynamic phase is followed by a hadronic rescattering stage. The…
Investigation of the p–Σ0 interaction via femtoscopy in pp collisions
2020
This Letter presents the first direct investigation of the p-$\Sigma^{0}$ interaction, using the femtoscopy technique in high-multiplicity pp collisions at $\sqrt{s}$ = 13 TeV measured by the ALICE detector. The $\Sigma^{0}$ is reconstructed via the decay channel to $\Lambda \gamma$, and the subsequent decay of $\Lambda$ to p$\pi^-$. The photon is detected via the conversion in material to e$^{+}$e$^{-}$ pairs exploiting the unique capability of the ALICE detector to measure electrons at low transverse momenta. The measured p-$\Sigma^{0}$ correlation indicates a shallow strong interaction. The comparison of the data to several theoretical predictions obtained employing the $Correlation~Anal…
Scattering Studies with Low-Energy Kaon-Proton Femtoscopy in Proton-Proton Collisions at the LHC
2020
The study of the strength and behaviour of the antikaon-nucleon ($\mathrm{\overline{K}N}$) interaction constitutes one of the key focuses of the strangeness sector in low-energy Quantum Chromodynamics (QCD). In this letter a unique high-precision measurement of the strong interaction between kaons and protons, close and above the kinematic threshold, is presented. The femtoscopic measurements of the correlation function at low pair-frame relative momentum of (K$^+$ p $\oplus$ K$^-$ $\overline{\mathrm{p}}$) and (K$^-$ p $\oplus$ K$^+$ $\overline{\mathrm{p}}$) pairs measured in pp collisions at $\sqrt{s}$ = 5, 7 and 13 TeV are reported. A structure observed around a relative momentum of 58 Me…
Identification of a Novel Pathway in BCR/ABL Signal Transduction Involving Akt-Independent Activation of PLC-gamma/mTOR/p70-S6K.
2006
Abstract In BCR/ABL positive CML, defining new, additional therapeutic targets in the pathways, activated by BCR/ABL is critical for the development of new treatment strategies, especially for patients resistant or refractory to Imatinib. While studying the involvement of PI3K/Akt/mTOR signaling pathway in the development of such resistance we have uncovered the existence of additional, Akt-independent mechanism of activation of mTOR/p70-S6 Kinase pathway. Short term treatment with Imatinib (1μM, 4 hours) of the BCR/ABL-positive cell lines LAMA84, AR320, KCL22, K562, Ba/F3-BCR/ABL caused downregulation of p70-S6K phosphorylation and of S6 ribosomal protein phosphorylation without decreasing…
Metformin influences drug sensitivity in pancreatic cancer cells
2018
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction o…
Femtosecond up-conversion technique for probing the charge transfer in a P3HT : PCBM blend via photoluminescence quenching
2009
We report on an experimental study of the charge transfer dynamics in a P3HT : PCBM blend by means of a femtosecond fluorescence up-conversion technique. Using two-photon excitation we probe the exciton dynamics in P3HT and a P3HT : PCBM blend with a weight ratio of 1 : 1 at excitation densities of up to 6 × 1018 cm−3. In both samples we find strongly nonexponential decay traces compatible with (i) diffusion-limited exciton–exciton annihilation and (ii) diffusion-limited donor–acceptor charge transfer in the polymer blend. Additionally, our results indicate that in the P3HT : PCBM blend about 50% of the photogenerated excitons undergo a prompt charge transfer process on a time scale of abou…
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
2016
// Daniela Massihnia 1,* , Antonio Galvano 1,* , Daniele Fanale 1 , Alessandro Perez 1 , Marta Castiglia 1 , Lorena Incorvaia 1 , Angela Listi 1 , Sergio Rizzo 1 , Giuseppe Cicero 1 , Viviana Bazan 1 , Sergio Castorina 2,3,** and Antonio Russo 1,** 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors have contributed equally to this work ** Both the authors are last name Correspondence to: Antonio Russo, email: // Keywords : ER, HER2, PI3K/AKT/mTOR inhib…
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…
2014
Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
2011
Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid …
2016
Abstract Activation of AKT signaling by PTEN loss or PIK3CA mutations occurs frequently in human cancers, but targeting AKT has been difficult due to the mechanism-based toxicities of inhibitors that target the inactive conformation of AKT. Ipatasertib (GDC-0068) is a novel selective ATP-competitive small-molecule inhibitor of AKT that preferentially targets active phosphorylated AKT (pAKT) and is potent in cell lines with evidence of AKT activation. In this phase I study, ipatasertib was well tolerated; most adverse events were gastrointestinal and grade 1–2 in severity. The exposures of ipatasertib ≥200 mg daily in patients correlated with preclinical TGI90, and pharmacodynamic studies co…